Nanox (NASDAQ: NNOX) has entered into a distribution agreement with SOLME RC, S.A., a Costa Rica-based medical equipment distributor, to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. The agreement positions Nanox to penetrate a new market in Latin America, following recent entries into Argentina and Peru. SOLME will handle marketing, distribution, installation, training, and ongoing technical support in Costa Rica, where it is a registered supplier to the Caja Costarricense de Seguro Social (CCSS), the country's principal purchaser and provider of hospital services.
This development matters because it signals Nanox's continued execution of its global expansion strategy, particularly in regions where access to advanced medical imaging is limited. By partnering with a local distributor that already has a relationship with the CCSS, Nanox gains a direct channel to Costa Rica's public healthcare system. Commercialization will proceed after applicable regulatory registration, including an initial six-month proof-of-concept device registration period before full registration. This phased approach allows for clinical validation and builds confidence among local stakeholders before broader deployment.
The Nanox.ARC is a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability. It is part of a broader ecosystem that includes Nanox.AI, a suite of AI-based algorithms that augment the interpretation of routine CT imaging to identify early signs often associated with chronic disease; Nanox.CLOUD, a cloud-based platform for secure data management, storage, and advanced imaging analytics; Nanox.MARKETPLACE and USARAD Holdings, which provide access to remote radiology and cardiology experts and comprehensive teleradiology services; and Nanox Health IT, which combines deep healthcare IT expertise with leading technology partners to deliver RIS, PACS, AI, dictation, and secure infrastructure solutions that streamline workflows and support safer, more efficient care delivery.
For Costa Rica, the agreement could mean improved access to advanced imaging, which is critical for early detection and preventive care. The CCSS is the primary provider of hospital services in the country, and its adoption of Nanox.ARC could set a precedent for other public health systems in the region. The proof-of-concept period will likely serve as a real-world evaluation of the technology's performance and integration into existing workflows, potentially influencing broader adoption across Latin America.
Nanox's vision is to expand the reach of medical imaging both within and beyond traditional hospital settings by providing a seamless solution from scan to interpretation and beyond. By leveraging proprietary digital X-ray technology, AI-driven analytics, and a clinically driven approach, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes. The Costa Rica agreement is a tangible step toward that vision, demonstrating the company's ability to secure distribution partners in new markets and navigate regulatory processes.
Investors and industry observers will be watching how quickly Nanox can move through the registration process and whether the proof-of-concept leads to full-scale adoption. The company's forward-looking statements caution that actual results may differ materially due to various risks and uncertainties, including those detailed in its SEC filings. Nevertheless, the agreement underscores Nanox's commitment to driving the world's transition to preventive health care by making imaging more accessible and affordable. For more details, see the full press release at https://ibn.fm/C77lJ. The latest news and updates relating to NNOX are available in the company's newsroom at https://ibn.fm/NNOX.
